The PI3K/AKT/mTOR signaling pathway is frequently dysregulated in NSCLC, primarily due to various genetic and epigenetic alterations, including mutations or overexpression of EGFR [33,34]. This evidence concerns the gene MTOR and non-small cell lung carcinoma.